Nuvation Bio Inc (NYSE:NUVB) — Market Cap & Net Worth
Market Cap & Net Worth: Nuvation Bio Inc (NUVB)
Nuvation Bio Inc (NYSE:NUVB) has a market capitalization of $2.05 Billion ($2.05 Billion) as of September 21, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #6120 globally and #1954 in its home market, demonstrating a -6.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvation Bio Inc's stock price $5.85 by its total outstanding shares 350123233 (350.12 Million). Also see balance sheet size of Nuvation Bio Inc for a full breakdown of the balance sheet.
Nuvation Bio Inc Market Cap History: 2020 to 2026
Nuvation Bio Inc's market capitalization history from 2020 to 2026. Data shows change from $4.10 Billion to $2.05 Billion (-8.45% CAGR). Also see NUVB cash generation efficiency for how efficiently the company converts equity into cash flow.
Nuvation Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvation Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Nuvation Bio Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
49.87x
Nuvation Bio Inc's market cap is 49.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $931.33 Million | $7.87 Million | -$567.94 Million | 118.29x | N/A |
| 2025 | $3.14 Billion | $62.90 Million | -$204.63 Million | 49.87x | N/A |
Competitor Companies of NUVB by Market Capitalization
Companies near Nuvation Bio Inc in the global market cap rankings as of September 21, 2026. Review NUVB goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nuvation Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Nuvation Bio Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Nuvation Bio Inc's market cap moved from $4.10 Billion to $ 2.05 Billion, with a yearly change of -8.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.05 Billion | -34.71% |
| 2025 | $3.14 Billion | +236.84% |
| 2024 | $931.33 Million | +76.16% |
| 2023 | $528.69 Million | -21.35% |
| 2022 | $672.24 Million | -77.41% |
| 2021 | $2.98 Billion | -27.35% |
| 2020 | $4.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Nuvation Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.05 Billion USD |
| MoneyControl | $2.05 Billion USD |
| MarketWatch | $2.05 Billion USD |
| marketcap.company | $2.05 Billion USD |
| Reuters | $2.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more